|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
5
|
|
pubmed:dateCreated |
1993-5-27
|
|
pubmed:abstractText |
We performed a Phase I trial to determine the maximum tolerated dose of combined pre-operative radiation (5040 cGy) and 2 cycles (bolus daily x 5) of 5-FU and low dose LV (20 mg/m2), followed by surgery and 10 cycles of post-operative LV/5-FU in patients with unresectable primary or recurrent rectal cancer.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0360-3016
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
2
|
|
pubmed:volume |
25
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
821-7
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:8478232-Adult,
pubmed-meshheading:8478232-Aged,
pubmed-meshheading:8478232-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:8478232-Combined Modality Therapy,
pubmed-meshheading:8478232-Female,
pubmed-meshheading:8478232-Fluorouracil,
pubmed-meshheading:8478232-Humans,
pubmed-meshheading:8478232-Leucovorin,
pubmed-meshheading:8478232-Male,
pubmed-meshheading:8478232-Middle Aged,
pubmed-meshheading:8478232-Prospective Studies,
pubmed-meshheading:8478232-Radiotherapy,
pubmed-meshheading:8478232-Rectal Neoplasms
|
|
pubmed:year |
1993
|
|
pubmed:articleTitle |
Pre-operative combined 5-FU, low dose leucovorin, and sequential radiation therapy for unresectable rectal cancer.
|
|
pubmed:affiliation |
Department of Radiation Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
